modelA06AD02
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | MagnesiumOxide | |
| ATC code: | A06AD02 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 0.3 | L |
| clearance: | 6 | L/h |
| other parameters in model implementation | ||
Magnesium oxide is an inorganic compound used as a dietary supplement in individuals with magnesium deficiency, and as an antacid and laxative. It is commonly employed for short-term relief of heartburn, dyspepsia, and constipation. Magnesium oxide remains in use and is approved in multiple countries for these indications.
Pharmacokinetics
Estimated oral pharmacokinetic parameters for healthy adults. No published source with detailed compartmental PK parameters; magnesium oxide is poorly absorbed when administered orally and acts primarily in the gastrointestinal tract.
References
Kashihara, Y, et al., & Ieiri, I (2019). Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. European journal of clinical pharmacology 75(3) 351–361. DOI:10.1007/s00228-018-2568-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30382297
Hoy, SM, et al., & Wagstaff, AJ (2009). Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 69(1) 123–136. DOI:10.2165/00003495-200969010-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19192941
Schuette, SA, et al., & Janghorbani, M (1994). Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN. Journal of parenteral and enteral nutrition 18(5) 430–435. DOI:10.1177/0148607194018005430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7815675
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)